FDMT - CIK 0001650648
4D Molecular Therapeutics, Inc. (FDMT) reported revenue of $85.21M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $85.21M | +230194.6% |
| FY 2024 | $37.00K | -99.8% |
| FY 2023 | $20.72M | +562.3% |
| FY 2022 | $3.13M | -82.7% |
| FY 2021 | $18.04M | +32.5% |
| FY 2020 | $13.61M | +94.8% |
| FY 2019 | $6.99M | - |
4D Molecular Therapeutics, Inc. (FDMT) reported revenue of $85.21M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, 4D Molecular Therapeutics, Inc.'s revenue grew from $6.99M to $85.21M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.